However, the overall clinical outcomes of the patient cohort suggest that CD19/CD22 BS Loop CAR-T-cell therapy offers significant clinical benefits for treating highly aggressive and lethal B-cell malignant lymphoma, particularly r/r DLBCL. The gene discussed is CD22; the disease is diffuse large B-cell lymphoma.